drugset / Trial / NCT02637973
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Phase 4
Completed
84 enrolled
The Deutsche Diabetes Forschungsgesellschaft e.V.
Boehringer Ingelheim · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a multicentre, prospective, placebo-controlled, double-blind, randomized, 2-arm parallel, interventional and exploratory pilot study in patients with newly diagnosed type 2 diabetes.
Timeline
- Start
- 2015-12
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | — |